Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Amortizatization of Intangibles: 2019-2025

Historic Amortizatization of Intangibles for UroGen Pharma (URGN) over the last 7 years, with Sep 2025 value amounting to $160,000.

  • UroGen Pharma's Amortizatization of Intangibles fell 93.02% to $160,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.1 million, marking a year-over-year increase of 95.02%. This contributed to the annual value of $2.9 million for FY2024, which is 179.59% up from last year.
  • According to the latest figures from Q3 2025, UroGen Pharma's Amortizatization of Intangibles is $160,000, which was down 81.52% from $866,000 recorded in Q2 2025.
  • UroGen Pharma's Amortizatization of Intangibles' 5-year high stood at $2.3 million during Q3 2024, with a 5-year trough of -$961,000 in Q1 2024.
  • Its 3-year average for Amortizatization of Intangibles is $520,455, with a median of $355,000 in 2023.
  • Data for UroGen Pharma's Amortizatization of Intangibles shows a peak YoY increase of 2,420.75% (in 2024) and a maximum YoY decrease of 337.87% (in 2024) over the last 5 years.
  • Over the past 5 years, UroGen Pharma's Amortizatization of Intangibles (Quarterly) stood at $238,000 in 2021, then surged by 184.45% to $677,000 in 2022, then tumbled by 92.17% to $53,000 in 2023, then spiked by 2,420.75% to $1.3 million in 2024, then tumbled by 93.02% to $160,000 in 2025.
  • Its Amortizatization of Intangibles was $160,000 in Q3 2025, compared to $866,000 in Q2 2025 and $774,000 in Q1 2025.